Viewing nowMonorova Tablet 10mg (Rosuvastatin Calcium)
Rosuvastatin Calcium 10.4mg
Tablet · Prescription medication
Yuhan Corporation

MFDS item code 201400102 · Approved 2014.01.10 · Insurance code 642104410
Improves dyslipidemia, reduces the risk of cardiovascular disease, and inhibits the progression of atherosclerosis
This medication is primarily used for various conditions related to hypercholesterolemia. It is used as an adjunct therapy in cases of primary hypercholesterolemia or mixed dyslipidemia that are not controlled by diet and exercise. It is also used in conjunction with existing treatments for patients with homozygous familial hypercholesterolemia to lower blood cholesterol levels. This drug effectively reduces total cholesterol and LDL-cholesterol to slow the progression of atherosclerosis. It is particularly suitable for pediatric patients aged 10-17 with heterozygous familial hypercholesterolemia. It is also utilized as an adjunct to dietary therapy for patients with primary dysbetalipoproteinemia. In high-risk patients with elevated high-sensitivity C-reactive protein levels and additional cardiovascular disease risk factors, it is expected to reduce the risk of myocardial infarction, stroke, and vascular revascularization. Therefore, this medication is used to improve the risks associated with dyslipidemia and cardiovascular diseases.
1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine, and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to a maintenance dose. The maintenance dose is 10 milligrams once daily, which is sufficient to control the condition in most patients. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or more, according to LDL cholesterol levels, the treatment goal, and the patient's response; the dose may be increased to a maximum of 20 milligrams daily. 3. Elderly patients: No dose adjustment is required. 4. Patients with renal impairment: No dose adjustment is required in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Use particular caution when administering this medicine 20mg to patients with moderate renal impairment. 5. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or lower, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Assessment of renal function should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 6. Race: As systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 7. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose is contraindicated in some of these patients.
Age 10 to 17 years: The usual dose range is 5 milligrams to 20 milligrams once daily. (There are no clinical data on administration of doses higher than 20 milligrams in pediatric patients.) Under 10 years: Safety and efficacy have not been established.
This medication should not be used in certain patients. For example, patients with allergies to this drug's ingredients, patients with severely impaired liver function, those with muscular disorders, patients with severe renal impairment, and women who are pregnant or breastfeeding should not take this medication. Additionally, liver function tests should be conducted before and during this medication. Caution is advised for those with liver disease or hypothyroidism. If symptoms of myalgia or muscle weakness occur, notify medical personnel immediately, and in severe cases, discontinue use of the drug. This medication can interact with some other drugs, so if you are currently taking any other medications, you must inform your doctor or pharmacist. In particular, there may be an increased risk of muscle-related side effects when used in combination with certain antiviral medications, immunosuppressants, or fibrates. Women who are pregnant or planning to become pregnant should use appropriate contraception and should discontinue this medication immediately if pregnancy is confirmed. It is also advisable for breastfeeding women to avoid taking this medication. In case of overdose, there is no specific antidote, and treatment should be symptom-based, monitoring liver function and muscle enzyme levels. This medication can rarely cause side effects such as skin rash, abnormal liver function, neurological issues, and muscle damage, so consult medical personnel immediately if any symptoms arise. Caution is advised when driving or operating machinery as dizziness may occur.
Hypersensitivity reactions including angioedema, diabetes, headache, dizziness, constipation, nausea, abdominal pain, pancreatitis, itching, rash, urticaria, myalgia, myopathy, rhabdomyolysis, weakness, polyneuropathy, amnesia, peripheral neuropathy, myasthenia gravis, cough, dyspnea, diarrhea, oculomotor weakness, thrombocytopenia, jaundice, hepatitis, increased transaminases, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms (DRESS), fixed drug eruption, lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, interstitial lung disease, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, cognitive impairment, increased ALT, chest pain, muscle cramps, gout, erectile dysfunction, numbness, paraesthesia, chest discomfort, decreased appetite, abdominal distension, syncope, generalized pain, fatigue
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly closed container to protect it from air and moisture. It is important to maintain a storage temperature of 1 to 30 degrees Celsius. This helps to ensure that the medication remains effective and safe to use.
Pink round film-coated tablet
30 tablets/bottle, 100 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowRosuvastatin Calcium 10.4mg
Tablet · Prescription medication
Yuhan Corporation

Rosuvastatin Calcium 10.4mg
Tablet · Prescription medication
AstraZeneca Korea Co., Ltd.

Rosuvastatin Calcium 20.8mg
Tablet · Prescription medication
AstraZeneca Korea Co., Ltd.

Rosuvastatin Calcium 5.2mg
Tablet · Prescription medication
AstraZeneca Korea Co., Ltd.

Rosuvastatin Calcium 10.4mg
Tablet · Prescription medication
Chong Kun Dang Pharmaceutical Corp.

Rosuvastatin Calcium 10.4mg
Tablet · Prescription medication
Dong Gu Bio Pharmaceutical Co., Ltd.

Rosuvastatin Calcium 10.4mg
Tablet · Prescription medication
Boryung Pharmaceutical Co., Ltd.

Rosuvastatin Calcium 20.8mg
Tablet · Prescription medication
Jongkundang Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.